Navigation Links
Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology

http://www.reportlinker.com/p0512134/Innovations-in-Protein-Kinase-Therapies---Significant-Proportion-of-Protein-Kinase-Pipeline-Contains-Small-Molecule-Drugs-That-Target-Oncology.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Sport_Nutritional

Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology

Summary

GBI Research's report, "Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology", provides in-depth analysis of innovations in protein kinase therapies in the current pharmaceutical market. The report analyzes the protein kinase pipelines of pharmaceutical companies by indication, and also according to the phase of clinical trial. This report includes protein kinase pipeline profiles of the top 10 pharmaceutical companies based on their pipeline. It gives you a robust idea on pipeline, innovations in various indications, new strategies employed for innovation, trends in combination drugs and protein kinase targets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The current R&D product pipeline targeting protein kinases consists of a majority of the molecules in Phase II. Phase II contains 57% of the total molecules, followed by Phase I, Phase III, Pre-clinical, and Discovery phases, accounting to 29%, 8%, 5%, and 1% respectively. Oncology has the highest number of pipeline drugs, accounting for 92% of total indications. The pipeline seems to be outsized when compared with the last few years, and it is growing strategically with increased focus on protein kinases. In particular, the oncology indication gained a lot of attention, and protein kinases with their specificity took a major stake in oncology pipeline molecules.

Scope

The scope of this report includes -

- Detailed classification of protein kinase pipeline molecules.

- Pipeline product analysis, category-wise and Phase-wise study.

- Profiles of the top 10 companies with key pipeline products, indication-wise and Phase-wise analysis.

- An overview of current innovative strategies in the protein kinase therapies development by pharmaceutical companies.

Reasons to buy

The report will aid business development and marketing executives in strategizing their product launches and help venture capitalists to identify promising small and medium sized enterprises. It will allow you to -

- Assess the strength of the protein kinase pipeline of current pharmaceutical companies.

- Understand the potential areas of application for protein kinase therapies.

- Identify key protein kinases in development based on the therapy.

- Identify the key players investing in protein kinase therapies.

- Optimize your R&D pipeline through identification and understanding of the key pipeline products of competitors.

- Develop effective strategies related to innovations in protein kinase therapies by identifying the new targets in development.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Protein Kinases – Introduction 10

2.1 GBI Research Report Guidance 10

3 Protein Kinases – Overview 11

3.1 Localization and Function in the Cell 11

3.2 The Human Kinome 11

3.3 Kinase Classification 12

3.3.1 AGC Family 13

3.3.2 CAMK Family 14

3.3.3 CMGC Family 15

3.3.4 CK1 Family 16

3.3.5 STE Family 17

3.3.6 TK Family 18

3.3.7 TKL Family 19

3.3.8 Atypical Protein Kinases 20

3.4 Protein Kinases as Therapeutic Targets 21

3.4.1 The Cell Surface Kinases 21

3.4.2 The Cytoplasmic Protein Kinases 21

4 Protein Kinases – Pipeline Status for Major Indications 22

4.1 Oncology 24

4.1.1 Introduction 24

4.1.2 Pipeline Profile 24

4.1.3 Pipeline Analysis of Companies with Three or More Pipeline Molecules 25

4.1.4 NDA Applications Filed in Oncology 27

4.1.5 Phase III Pipeline Analysis Based on First-in-Class and Combination Drugs 27

4.2 Hematological Disorders 28

4.2.1 Introduction 28

4.2.2 Pipeline Analysis 28

4.3 Immunology 32

4.3.1 Introduction 32

4.3.2 Pipeline Analysis 32

4.4 Metabolic Disorders 36

4.4.1 Introduction 36

4.4.2 Pipeline Analysis 36

4.5 Central Nervous System 39

4.5.1 Introduction 39

4.5.2 Pipeline Analysis 40

4.6 Cardiovascular Diseases 44

4.6.1 Introduction 44

4.6.2 Pipeline Analysis 44

4.7 Ophthalmology 46

4.7.1 Introduction 46

4.7.2 Pipeline Analysis 46

5 Protein Kinases – Current Pipeline Analysis 49

5.1 Protein Kinases Pipeline Overview 49

5.2 Protein Kinase Pipeline Profile of Top 10 Companies 50

5.3 Pfizer 52

5.3.1 Overview 52

5.3.2 Pipeline Analysis 52

5.3.3 Key Indications of Interest 53

5.3.4 First-in-Class and Combination Drugs 54

5.4 GlaxoSmithKline plc 62

5.4.1 Overview 62

5.4.2 Pipeline Analysis 62

5.4.3 Key Indications of Interest 63

5.4.4 First-in-Class and Combination Drugs 64

5.5 Eli Lilly and Company 69

5.5.1 Overview 69

5.5.2 Pipeline Analysis 69

5.5.3 Key Indications of Interest 70

5.5.4 First-in-Class and Combination Drugs 71

5.6 AstraZeneca PLC 77

5.6.1 Overview 77

5.6.2 Pipeline Analysis 78

5.6.3 Key Indications of Interest 79

5.6.4 First-in-Class and Combination Drugs 80

5.7 F. Hoffmann-La Roche Ltd. 85

5.7.1 Overview 85

5.7.2 Pipeline Analysis 85

5.7.3 Key Indications of Interest 86

5.7.4 First-in-Class and Combination Drugs 87

5.8 Novartis 90

5.8.1 Overview 90

5.8.2 Pipeline Analysis 90

5.8.3 Key Indications of Interest 91

5.8.4 First-in-Class and Combination Drugs 92

5.9 Exelixis, Inc. 95

5.9.1 Overview 95

5.9.2 Pipeline Analysis 95

5.9.3 Key Indications of Interest 96

5.9.4 First-in-Class and Combination Drugs 97

5.10 Boehringer Ingelheim GmbH 100

5.10.1 Overview 100

5.10.2 Pipeline Analysis 100

5.10.3 Key Indications of Interest 101

5.10.4 First-in-Class and Combination Drugs 102

5.11 Merck Inc. 105

5.11.1 Overview 105

5.11.2 Pipeline Analysis 105

5.11.3 Key Indications of Interest 106

5.11.4 First-in-Class and Combination Drugs 107

5.12 Takeda Pharmaceutical Company Limited 111

5.12.1 Overview 111

5.12.2 Pipeline Analysis 111

5.12.3 Key Indications of Interest 112

5.12.4 First-in-Class and Combination Drugs 113

6 Protein Kinases – Trends in Patenting 115

7 Protein Kinases – Key Strategies for Innovation in Protein Kinases 116

7.1 Translational Science to Explore Multiple Disease Indications of Pipeline Drugs 116

7.2 The Strategy of Drug Combinations will Play a Significant Role in Development Programs 116

7.3 Focused Strategy for Drug Development 116

7.4 Functional Genomics 116

7.5 Distinctive R&D Strategies 116

8 Appendix 117

8.1 Market Definitions 117

8.2 Abbreviations 117

8.3 Research Methodology 117

8.3.1 Coverage 118

8.3.2 Secondary Research 118

8.3.3 Primary Research 118

8.3.4 Expert Panel Validation 118

8.4 Contact Us 119

8.5 Disclaimer 119

8.6 Sources 119

1.1 List of Tables

Table 1: Innovations in Protein Kinase Therapies – Protein Kinase Classification 12

Table 2: Innovations in Protein Kinase Therapies – Indication-Wise Protein Kinase Pipeline Status, 2010 23

Table 3: Innovations in Protein Kinase Therapies – Oncology Pipeline Profile, 2010 24

Table 4: Innovations in Protein Kinase Therapies – Companies With More Than Three Oncology Phase III Pipeline Molecules, 2010 26

Table 5: Innovations in Protein Kinase Therapies – NDA Applications Filed for Oncology Pipeline Molecules, 2010 27

Table 6: Innovations in Protein Kinase Therapies – Hematological Disorders Pipeline Status, 2010 28

Table 7: Innovations in Protein Kinase Therapies – List of Protein Kinase Pipeline Molecules in Hematological Disorders 29

Table 8: Innovations in Protein Kinase Therapies – Immunology Pipeline Status, 2010 32

Table 9: Innovations in Protein Kinase Therapies – List of Protein Kinase Pipeline Molecules in Immunology 33

Table 10: Innovations in Protein Kinase Therapies – Metabolic Disorders Pipeline Status, 2010 36

Table 11: Innovations in Protein Kinase Therapies – List of Protein Kinase Pipeline Molecules in Metabolic Disorders 37

Table 12: Innovations in Protein Kinase Therapies – Central Nervous System Pipeline Status, 2010 40

Table 13: Innovations in Protein Kinase Therapies – List of Protein Kinase Pipeline Molecules in Central Nervous System 41

Table 14: Innovations in Protein Kinase Therapies – Cardiovascular Diseases Pipeline Status, 2010 44

Table 15: Innovations in Protein Kinase Therapies – List of Protein Kinase Pipeline Molecules in Cardiovascular Diseases 45

Table 16: Innovations in Protein Kinase Therapies – Ophthalmology Pipeline Status, 2010 46

Table 17: Innovations in Protein Kinase Therapies – List of Protein Kinase Pipeline Molecules in Ophthalmology 47

Table 18: Innovations in Protein Kinase Therapies – Overview of Protein Kinase Pipeline for all the Indications, 2010 49

Table 19: Innovations in Protein Kinase Therapies – Protein Kinase Pipeline Status of Top 10 Companies, 2010 51

Table 20: Innovations in Protein Kinase Therapies – Pfizer Protein Kinase Pipeline Status, 2010 52

Table 21: Innovations in Protein Kinase Therapies, Pfizer, No. of Protein Kinase Molecules Based on Indication, 2010 53

Table 22: Innovations in Protein Kinase Therapies – List of Pfizer Protein Kinase Pipeline Studies 54

Table 23: Innovations in Protein Kinase Therapies – GlaxoSmithKline Protein Kinases Pipeline Status, 2010 62

Table 24: Innovations in Protein Kinase Therapies – GlaxoSmithKline, No. of Protein Kinase Molecules Based on Indication, 2010 63

Table 25: Innovations in Protein Kinase Therapies – List of GlaxoSmithKline Protein Kinase Pipeline Studies 64

Table 26: Eli Lilly Protein Kinases Pipeline Status, 2010 69

Table 27: Innovations in Protein Kinase Therapies – Eli Lilly, No. of Protein Kinase Molecules Based on Indication, 2010 70

Table 28: Innovations in Protein Kinase Therapies – List of Eli Lilly Protein Kinase Pipeline Studies 71

Table 29: Innovations in Protein Kinase Therapies – AstraZeneca Protein Kinases Pipeline Status, 2010 78

Table 30: Innovations in Protein Kinase Therapies – AstraZeneca, No. of Protein Kinase Molecules Based on Indication, 2010 79

Table 31: Innovations in Protein Kinase Therapies – List of AstraZeneca Protein Kinase Pipeline Studies 80

Table 32: Innovations in Protein Kinase Therapies – Roche Protein Kinases Pipeline Status, 2010 85

Table 33: Innovations in Protein Kinase Therapies – Roche, No. of Protein Kinase Molecules Based on Indication, 2010 86

Table 34: Innovations in Protein Kinase Therapies – List of Roche Protein Kinase Pipeline Studies 87

Table 35: Innovations in Protein Kinase Therapies – Novartis Protein Kinases Pipeline Status, 2010 90

Table 36: Innovations in Protein Kinase Therapies – Novartis, No. of Protein Kinase Molecules Based on Indication, 2010 91

Table 37: Innovations in Protein Kinase Therapies – List of Novartis Protein Kinase Pipeline Studies 92

Table 38: Innovations in Protein Kinase Therapies – Exelixis Protein Kinases Pipeline Status, 2010 95

Table 39: Innovations in Protein Kinase Therapies – Exelixis, No. of Protein Kinase Molecules Based on Indication, 2010 96

Table 40: Innovations in Protein Kinase Therapies – List of Exelixis Protein Kinase Pipeline Studies 97

Table 41: Innovations in Protein Kinase Therapies – Boehringer Ingelheim Protein Kinases Pipeline Status, 2010 100

Table 42: Innovations in Protein Kinase Therapies – Boehringer Ingelheim, No. of Protein Kinase Molecules Based on Indication, 2010 101

Table 43: Innovations in Protein Kinase Therapies – List of Boehringer Ingelheim Protein Kinase Pipeline Studies 102

Table 44: Innovations in Protein Kinase Therapies – Merck Protein Kinases Pipeline Status, 2010 105

Table 45: Innovations in Protein Kinase Therapies – Merck, No. of Protein Kinase Molecules Based on Indication, 2010 106

Table 46: Innovations in Protein Kinase Therapies – List of Merck Protein Kinase Pipeline Studies 107

Table 47: Innovations in Protein Kinase Therapies – Takeda Protein Kinases Pipeline Status, 2010 111

Table 48: Innovations in Protein Kinase Therapies – Takeda, No. of Protein Kinase Molecules Based on Indication, 2010 112

Table 49: Innovations in Protein Kinase Therapies – List of Takeda Protein Kinase Pipeline Studies 113

1.2 List of Figures

Figure 1: Innovations in Protein Kinase Therapies – The Human Kinome Family 11

Figure 2: Innovations in Protein Kinase Therapies – AGC Family Kinases 13

Figure 3: Innovations in Protein Kinase Therapies – CAMK Family Kinases 14

Figure 4: Innovations in Protein Kinase Therapies – CMGC Family Kinases 15

Figure 5: Innovations in Protein Kinase Therapies – CK1 Family Kinases 16

Figure 6: Innovations in Protein Kinase Therapies – STE Family Kinases 17

Figure 7: Innovations in Protein Kinase Therapies – TK Family Kinases 18

Figure 8: Innovations in Protein Kinase Therapies – TKL Family Kinases 19

Figure 9: Innovations in Protein Kinase Therapies – Atypical Family Kinases 20

Figure 10: Innovations in Protein Kinase Therapies – Protein Kinases in Development for Major Indications 22

Figure 11: Innovations in Protein Kinase Therapies – Oncology Pipeline Profile, 2010 24

Figure 12: Innovations in Protein Kinase Therapies – Oncology Phase III Pipeline Analysis of Companies With Three or More Pipeline Molecules, 2010 25

Figure 13: Innovations in Protein Kinase Therapies – Oncology Phase III Pipeline Analysis Based on First-in-Class and Combination Drugs, 2010 27

Figure 14: Innovations in Protein Kinase Therapies – Hematological Disorders Pipeline Profile, 2010 28

Figure 15: Innovations in Protein Kinase Therapies – Immunology Pipeline Profile, 2010 32

Figure 16: Innovations in Protein Kinase Therapies – Metabolic Disorders Pipeline Profile, 2010 36

Figure 17: Innovations in Protein Kinase Therapies – Central Nervous System Pipeline Profile, 2010 40

Figure 18: Innovations in Protein Kinase Therapies – Cardiovascular Diseases Pipeline Profile, 2010 44

Figure 19: Innovations in Protein Kinase Therapies – Ophthalmology Pipeline Profile, 2010 46

Figure 20: Innovations in Protein Kinase Therapies – Protein Kinases Pipeline Overview, 2010 49

Figure 21: Innovations in Protein Kinase Therapies – Protein Kinase Pipeline Profile of Top 10 Companies, 2010 50

Figure 22: Innovations in Protein Kinase Therapies – Pfizer Protein Kinases Phase-Wise Pipeline Profile, 2010 52

Figure 23: Innovations in Protein Kinase Therapies – Pfizer Protein Kinase Pipeline Status for Various Indications, 2010 53

Figure 24: Innovations in Protein Kinase Therapies – GlaxoSmithKline Protein Kinases Pipeline Profile, 2010 62

Figure 25: Innovations in Protein Kinase Therapies – GlaxoSmithKline Protein Kinase Pipeline Status for Various Indications, 2010 63

Figure 26: Innovations in Protein Kinase Therapies – Eli Lilly Protein Kinases Pipeline Profile, 2010 69

Figure 27: Innovations in Protein Kinase Therapies – Eli Lilly Protein Kinase Pipeline Status for Various Indications, 2010 70

Figure 28: Innovations in Protein Kinase Therapies – AstraZeneca Protein Kinases Pipeline Profile, 2010 78

Figure 29: Innovations in Protein Kinase Therapies – AstraZeneca Protein Kinase Pipeline Status for Various Indications, 2010 79

Figure 30: Innovations in Protein Kinase Therapies – Roche Protein Kinases Pipeline Profile, 2010 85

Figure 31: Innovations in Protein Kinase Therapies – Roche Protein Kinase Pipeline Status for Various Indications, 2010 86

Figure 32: Innovations in Protein Kinase Therapies – Novartis Protein Kinases Pipeline Profile, 2010 90

Figure 33: Innovations in Protein Kinase Therapies – Novartis Protein Kinase Pipeline Status for Various Indications, 2010 91

Figure 34: Innovations in Protein Kinase Therapies – Exelixis Protein Kinases Pipeline Profile, 2010 95

Figure 35: Innovations in Protein Kinase Therapies – Exelixis Protein Kinase Pipeline Status for Various Indications, 2010 96

Figure 36: Innovations in Protein Kinase Therapies – Boehringer Ingelheim Protein Kinases Pipeline Profile, 2010 100

Figure 37: Innovations in Protein Kinase Therapies – Boehringer Ingelheim Protein Kinase Pipeline Status for Various Indications, 2010 101

Figure 38: Innovations in Protein Kinase Therapies – Merck Protein Kinases Pipeline Profile, 2010 105

Figure 39: Innovations in Protein Kinase Therapies – Merck Protein Kinase Pipeline Status for Various Indications, 2010 106

Figure 40: Innovations in Protein Kinase Therapies – Takeda Protein Kinases Pipeline Profile, 2010 111

Figure 41: Innovations in Protein Kinase Therapies – Takeda Protein Kinase Pipeline Status for Various Indications, 2010 112

Figure 42: Major Trends in Protein Kinases Patenting, 2010 115

Companies Mentioned

Pfizer

GlaxoSmithKline plc

Eli Lilly and Company

AstraZeneca PLC

F. Hoffmann-La Roche Ltd.

Novartis

Exelixis, Inc

Boehringer Ingelheim GmbH

Merck Inc.

Takeda Pharmaceutical Company Limited

To order this report:

Sport Nutritional Industry: Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology

Sport Nutritional Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug Obermann has ... his career at PBI-Gordon in February 1988, after finishing his masters in agronomy from ... from customer service to national product manager, to helping develop, name and launch many ...
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published ... of the state’s 76 fastest-growing private companies; a small percentage of the state's 615,000+ ... organizations on the percent change in revenue from 2012 to 2015. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech ... driven conferences, will take place on June 7-8, 2016, at the New York Academy ... on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville Fertility ... laboratories. A contingency of reproductive endocrinologists, including Dr. George Hill at ... and to help them build families. , Ovation Fertility is a nationwide network ...
Breaking Biology Technology:
(Date:3/3/2016)... March 3, 2016  2016FLEX, organized by FlexTech, ... highlighting advancements in flexible, hybrid and printed electronics. ... attendance - have gathered for short courses, technical ... of electronics. The Flex Conference celebrates its 15 ... companies, R&D organizations, and universities contributing to the ...
(Date:3/2/2016)... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ... "Global Biometrics Market in Hospitality Sector 2016-2020" ... , , Global biometrics market in the ... of around 27%   --> ... addition of the  "Global Biometrics Market in ...
(Date:3/1/2016)... DUBLIN , March 1, 2016 ... has announced the addition of the  ... 2015-2019"  report to their offering. ... announced the addition of the  "Global ...  report to their offering. ...
Breaking Biology News(10 mins):